Page last updated: 2024-11-13
3,4-dimethylmethcathinone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3,4-dimethylmethcathinone: a designer drug; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 52988261 |
| CHEBI ID | 189377 |
| MeSH ID | M000602329 |
Synonyms (17)
| Synonym |
|---|
| 3,4-dmmc |
| 1-(3,4-dimethylphenyl)-2-(methylamino)propan-1-one |
| CHEBI:189377 |
| 3,4-dimethylmethcathinone |
| 3,4-dimethylmethcathinone hydrochloride |
| 3,4-dmmc hcl |
| IBZRXTVDTGVBIS-UHFFFAOYSA-N |
| 1-propanone, 1-(3,4-dimethylphenyl)-2-(methylamino)- |
| C4EW58DTW5 , |
| 1082110-00-6 |
| (+/-)-1-(3,4-dimethylphenyl)-2-(methylamino)propan-1-one |
| J3.065.113H , |
| unii-c4ew58dtw5 |
| 1-(3,4-dimethylphenyl)-2-methylaminopropan-1-one |
| Q4634067 |
| DTXSID501016968 |
| PD048189 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Importantly, NAC was also able to prevent the cytotoxicity promoted by 6 tested drugs, ruling for an involvement of oxidative stress in the toxic events observed." | ( Structure-cytotoxicity relationship profile of 13 synthetic cathinones in differentiated human SH-SY5Y neuronal cells. Capela, JP; Carvalho, F; Costa, VM; de Lourdes Bastos, M; Gaspar, H; Santos, S; Soares, J, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| aromatic ketone | A ketone in which the carbonyl group is attached to an aromatic ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 37.96
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (37.96) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (16.67%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||